News: MediPharm Labs reports Q4 2018 Revenue $ 10.2 million and adjusted EBITDA $ 2.1 million

MediPharm Labs Corp. (TSX-V: LABS) (OTCQB: MLCPF) (FSE: MLZ) ("MediPharm Labs" or "Company"), a worldwide chief in specialised, research-based cannabis extraction, distillation, purification and Cannabinoid isolation is happy to announce the fourth quarter and full yr monetary outcomes for the yr ended December 31, 2018. Audited monetary statements and management discussions and analyzes of durations can be found at SEDAR.

Fourth Quarter 2018 Highlights [19659003] Turnover of $ 10.2 million, which begins on November 12 after Well being Canada has acquired a advertising authorization

$ four.0 million gross profit, 39% gross margin

Adjusted EBITDA ( 1) $ 2.1 million, adjusted EBITDA (1) 21%

Originally a totally licensed producer specializing solely in hashish extraction

Signed giant label hashish oil gross sales agreement with Canopy Progress Corporation for as much as 900 kg for 18 months

Extended licensed throughput capability from 50% to 150,000 kg per yr

Highlights of the entire 2018

• A strengthened administration workforce that enhances profound scientific, processing, provide chain, financial and regulatory experience
• Signed four multi-year toll agreements by James E. Wagner Cultivation Company, INDIVA Restricted, Emer ald Well being Therapeutics, Inc. and The Supreme Hashish Company Inc.
• Purchased three.eight million grams of dried hashish from various licensed producers to determine hashish oil to satisfy the demand of major shoppers
• Launched MediPharm Labs Australian Hashish Removing Plant License anticipated H2 / 19
• More than $ 25 million in fairness financing and debut as a public company on TSX Venture Change on October four, 2018
• The Raise & Co Canadian Cannabis Awards have been awarded early in the yr

“2018 was a breakthrough for MediPharille m Labs. We turned the first absolutely licensed producer specializing solely in extraction and fast-scaled operations to be the main market chief within the manufacture of high-quality pharmaceutical manufacturing of cannabis derivatives – the way forward for hashish, "stated CEO Patrick McCutcheon.

”We have now demonstrated our capability to increase our footprint shortly and to realize vital revenue and constructive money movement as a leading extraction professional just a few weeks after advertising authorization, and our robust operations have continued in 2019. The power of this efficiency strengthens our technique and funding. We are proud that the MediPharm Labs group stands out as a world leader in cannabis and produces tangible results with vital future potential.

2018 Key Monetary Measures Three Months Ended Yr Ended 31, 31. December 2018 2017 2018 2017 $ (000's) $ (000 & # 39; s) $ (000 & # 39; s) ) $ (000's) $ (000) 000 & # 39; s Revenue 10 198 – 10 198 – Gross Cowl 3,967 – 3,967 – 3,967 – three,967 – 19659032] 39% – ] 39% – Internet loss (three,552) (742) (eight,466) (996) (995) EBITDA (1) 2,129 (695) (875) (948) Adjusted EBITDA margin (1)% 21% – 21% – – – %) –

2019 Yearly Highlights

• Personal labeled Sa les offers value over $ 85 million for over 15 months in December 2018
• Great Personal Label Hashish ljymyynti 35 million dollars and a $ 13.5 million further choice in the course of the 13-month settlement signed with
• TerrAscend Corp .:'s cost arrangement
• The first LP extraction signed a world agreement of private label AusCann Group Holdings Ltd with. Canadian Oil Export from Canada to Australia for Heavy Obligation Cannabinoid Capsules
• White Label Solutions Platform for Unloading, Cleansing, Shaping, Dealing with and Distributing Corporations for Distribution of LP, Direct Promoting and Non-Cannabis Shopper Packaged Goods (CPG)
• Signed First White Label Agreement Formulating, Handling and Distributing Tincture Bottles For An Present Model Beginning From H2 2019
• Acquired Over 5,000 Kg Of Cannabis For Personal Label Hashish Oil Manufacturing f. Two Weeks In March
• Began Buying and selling OTCQB with "MLCPF" and FSE with "MLZ"

Mr. McCutcheon continued: “We are now working on an ambitious and well-planned action plan for 2019, which will enable MediPharm Labs to expand the interests of the first beneficiary. Strengthening production, increasing capacity, targeting on EU GMP certification, expanding product offering, developing R&D and IP products, signing new sales agreements and implementing acquisitions and international growth. ”

” Most importantly, all that is the start line. We look ahead to accelerating our progress globally as a result of the dimensions of the market that may be confirmed is growing and we’re strengthening our foothold by way of the legalization of the anticipated evaporators, edible drinks and drinks in our residence nation. We continue to benefit from the various alternatives that we will capitalize on by means of efficient capital deployment and continuous skilled activity to realize long-term shareholder worth. The company has targeted on acquiring cost-effective, bulk-dried cannabis deliveries, growing the wholesale of hashish focus (uncooked resin and distillates) and value-added products, providers and new businesses at house and abroad to overcome tolls

Broaden the White-Label platform that includes design , processing and distribution providers – The anticipated legalization of evaporators, edible drinks and beverages in October 2019 can also be expected to broaden the corporate's demonstrable markets and act as a catalyst to promote a wide range of direct consumer-oriented brands and non-cannabis shopper packaging corporations are in search of companions comparable to MediPharm Labs for design. , processing and distribution of provinces.

Adding cGMP Production Capacity – The corporate is beneath development in two further constructing strains at its Barrie plant, that are expected to increase their annual refining capability to 250,000 kilos on a total of 7 extraction strains. Utilizing the cGMP technique, several extraction strains provide the pliability to own specific buyer gadgets and considerably improve productivity. Flexibility across multiple extraction strains is changing, offering a continuous aggressive benefit in the hashish market
.

Attaining European Union GMP Certification at Barrie – Anticipated to be certified at H2209, enabling the corporate to satisfy vital European demand.

The right first international association in Australia – The Australian Middle of Excellence is predicted to work on H2209 until it is licensed and serves as a hub for Asia-Pacific. The plant is designed to supply cGMP requirements with an annual extraction capacity of about 75,000 kg of dried cannabis. The Australian region presents a robust backdrop to cultivation, when cultivation circumstances are more favorable when the corporate expects to accumulate regionally sourced manufacturing inputs.

Increase Secondary Extraction Properties – Promote industrial scale distillation and business chromatography to offer lively pharmaceutical components that require at the very least 99.9% cannabinoid purification. Improvement is underway in specialty chromatographic processing experiments starting with H2 2019.

Mergers and Joint Venture Opportunities – The corporate has created a strong alternative to repeat its unique business model in other jurisdictions and complementary acquisitions to extend and speed up organic progress.

2018 Financial Highlights

All dollar quantities are expressed in Canadian dollars until in any other case said.

Three months ended Yr ended 31. December, 31. December 2018 2017 2018 2017 ] $ (000 s) $ (000 s) $ (000 s) $ (000 s) 10198 – 10198 – Value (6,231 ) – (6,231 ) – Gross Coverage three,967 – 3,967 – – 19659111] Common Administrative Prices (1,749 ) (694 ) ( [1965909] (947 [1] 9659113]) Advertising and Gross sales Costs (597 ) – (1,272 ) – Share-based Declare Costs 19659113]) – (1,965 ) – Transaction Payment (4,230 ) – – – – Other Operating Prices (19 ) (19659103) (996 ) (1 ) (1 ) ] (three,366 ) ( 695 (948 ) [19659952] Monetary Revenue 22 22 22 16 16 16 64 16 Monetary Bills (198 ) (63 ) (478 ) [ (742 ) (8466 ) (995 ) Practical loss – reported ] ] (19659098) (8,552 ) (948 ) Add: Share-based Claims 738 738 738 ] 738 – 1,965 – Cost Transaction four,230 – 4,230 – Depreciation 528 [19659206] – – – Adjusted EBITDA (1) 2.129 (695 ) (875 ) (948 )

1. 1. 1. it does not have a standardized which means, so it is probably not corresponding to that of other issuers. Adjusted EBITDA is included in the Complementary Declaration as a result of management believes that such measurement supplies a better estimate of the Company's operations in a steady method by eliminating sure money funds and charges or positive factors which are non-recurring. Adjusted EBITDA is outlined as internet loss excluding curiosity, taxes, depreciation and share-based compensation and itemizing expenses. Adjusted EBITDA has limitations as an analytical software as a result of it does not embrace depreciation and amortization costs, interest revenue and bills, taxes, share-based compensation and transaction fees. Because of these limitations, adjusted EBITDA should not be thought-about as the only measure of the company's operations and should not be thought-about in isolation or as an alternative to analyzing the results reported by the corporate underneath IFRS. Probably the most immediately comparable measure for adjusted EBITDA in accordance with IFRS is the working end result (loss). The above is suitable with EBITDA adjusted for the company's working loss. For extra info, see “Co-ordination of Non-IFRS Measures” in the Company's Administration Dialogue and Evaluation for the Yr Ended December 31, 2018

      About MediPharm Labs Plc

      MediPharm Labs, founded in 2015, distinguishes the first firm in Canada that acquired ACMPR licensed producer of hashish oil manufacturing without first obtaining a hashish cultivation license. CGMP (present Good Manufacturing Practices) and ISO Normal Cleanroom and Crucial Surroundings Laboratory focuses on hashish concentration, so MediPharm Labs is ready to produce purified, pharmaceutical hashish oil and concentrates for superior derivatives. MediPharm Labs has invested in professional, research-driven teams, cutting-edge know-how, end-of-life manufacturing processes and dedicated amenities to deliver clean, protected and accurately delivered cannabis merchandise to sufferers and shoppers. MediPharm Labs' own brand program is a big marginal exercise for the company to accumulate hashish flowers and reduce it from its many product providing companions, to supply cannabis oil focus merchandise for resale globally underneath its own brand.

      MediPharm Labs has additionally via its subsidiary MediPharm Labs Australia Pty Ltd completed its software process with the Federal Company for Drug Management to unload and import medical hashish products into Australia.